Mode
Text Size
Log in / Sign up

Enteral nutrition therapy associated with clinical remission in 60% of Chinese inflammatory bowel disease patients over 6 weeksEnteral nutrition helps many IBD patients reach remission faster

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider enteral nutrition as a complementary strategy for inflammatory bowel disease, noting associations require prospective confirmation.

This retrospective cohort study examined 750 Chinese patients with Crohn's disease or ulcerative colitis who received enteral nutrition therapy. The follow-up period was 6 ± 2 weeks. The primary outcome was clinical remission, while secondary outcomes included nutritional markers, inflammatory indices, and quality of life.

Approximately 60% of patients achieved clinical remission. Remission rates were 62.5% for Crohn's disease versus 57.1% for ulcerative colitis. Improvements were observed in BMI, albumin, hemoglobin, CRP levels, and IBDQ scores. Full adherence was independently associated with higher odds of remission, with an odds ratio of 2.15 and a p-value less than 0.001. Longer enteral nutrition duration greater than 6 weeks was also independently associated with higher odds of remission.

Minor adverse effects occurred in 8% of patients. No serious adverse events were reported. The study design is retrospective, which limits causal inference. Prospective randomized trials are needed to confirm these associations and standardize protocols. Generalizability beyond Chinese inflammatory bowel disease patients is uncertain.

Enteral nutrition therapy supports a potential role as a complementary strategy in inflammatory bowel disease management. However, clinicians should interpret these findings cautiously given the observational nature of the evidence.

Imagine waking up feeling better after just a few weeks of a special diet. This is not a dream for people with inflammatory bowel disease. A new study shows how simple changes in eating can change lives.

Many people struggle with Crohn's disease or ulcerative colitis every single day. These conditions cause painful belly cramps, diarrhea, and fatigue. The stress of managing these symptoms affects work, school, and family life. Current treatments often focus on strong medicines that carry their own side effects.

But here is the twist. Doctors are now looking at food as medicine. Instead of just fighting the disease with drugs, they are using specific nutrition plans to heal the gut. This approach addresses the root cause of malnutrition that often worsens the illness.

Think of your gut like a busy factory. When it is inflamed, the machinery breaks down and cannot process food properly. Special formulas act like a gentle repair crew. They provide the exact building blocks your body needs without triggering an immune attack. This is different from regular food which might contain ingredients that irritate the lining.

The researchers looked at records from 750 patients in China. Half had Crohn's disease and half had ulcerative colitis. They tracked what the patients ate and how they felt over time. The team focused on elemental and semi-elemental formulas. These are liquids that are easy to digest and absorb.

Patients who used these formulas for about six weeks saw big changes. About 60% of them reached clinical remission. This means their symptoms stopped and their disease activity scores dropped significantly. Their body weight went up and their blood protein levels improved.

This doesn't mean this treatment is available yet.

The study found that sticking to the plan mattered most. People who drank the formula every day had twice the chance of getting better. Using the formula for longer than six weeks also helped more people feel good. Side effects were very rare and mostly minor issues like a bit of bloating.

Experts say this fits perfectly into current care plans. It works well alongside other medicines to keep the disease under control. The goal is to give the gut a break so it can heal itself naturally. This reduces the need for high doses of steroids or immunosuppressants.

For patients wondering if this is right for them, talk to your doctor first. Not everyone needs this specific type of liquid food. Your doctor will decide if your condition fits the study results. It is important to follow medical advice before changing your diet.

The study had some limits because it looked at past records. It did not follow patients forward in time like a new trial would. Also, the group was mostly from one country. More research is needed to confirm these results everywhere.

What happens next involves bigger trials to prove these findings. Doctors want to create standard rules for using this therapy. Until then, patients should discuss nutrition plans with their care team. Small steps toward better eating can lead to big gains in health.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
BackgroundEnteral nutrition (EN) is essential for Inflammatory Bowel Disease treatment. This applies mainly to Crohn’s disease (CD) and ulcerative colitis (UC) patients. The study evaluated the impact of EN treatment on clinical, nutritional, inflammatory, and quality of life outcomes in IBD patients. This study aimed to examine the association between EN therapy’s clinical, nutritional, inflammatory, and Quality of Life (QoL) effects on Inflammatory Bowel Disease patients.MethodsA retrospective study investigated 750 Chinese IBD patients. These patients had 400 CD and 350 UC diagnoses. Medical records provided data. EN formula, administration, calorie density, and duration were studied along with disease activity, nutritional markers including hemoglobin, albumin, and body mass index, and inflammatory indices like erythrocyte sedimentation rate. Validated IBDQ measures quality of life. Clinical remission was defined as a Crohn’s Disease Activity Index (CDAI) score < 150 for CD patients and a Mayo score ≤ 2 (with no individual subscore > 1) for UC patients, assessed after completion of EN therapy. Chi-square and t-tests were used for statistical analysis, with a significance level of p < 0.05.ResultsBaseline characteristics of 750 patients are comparable between groups. Elemental and semi-elemental formulas were more frequently prescribed in CD patients and were associated with higher caloric and protein intake (p < 0.05). Approximately 60% of patients achieved clinical remission after 6 ± 2 weeks of EN therapy (62.5% CD vs. 57.1% UC). Improvements in BMI, albumin, hemoglobin, and CRP were observed in patients receiving EN, along with increased IBDQ scores. Adverse effects were minor (8%). Full adherence (OR = 2.15, p < 0.001) and longer EN duration (>6 weeks) were independently associated with higher odds of remission and QoL improvement.ConclusionEN therapy corresponded with clinical remission, improved nutritional markers, and reduced inflammation in IBD patients, particularly those with CD. These findings support the potential role of EN as a complementary strategy in IBD management; however, prospective randomized trials are further confirming these associations and standardize therapeutic protocols.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.